ACP-105

ID: acp105

Aliases: ACP105

Type: compound

Route/form: oral preclinical SARM context

Status: research

Evidence level: mechanistic

Best data tier: direct mechanistic; case-report/safety context

Support scope: review/regulatory

Source types: forensic_toxicology, review

Linked sources: 2

Broad outcomes: Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor modulator
• nonsteroidal SARM

Optimization domains

• SARM
• doping
• toxicology
• unapproved context

Research basis

• Forensic/toxicology literature treats ACP-105 as a nonsteroidal SARM increasingly relevant to doping analyses.
• It is worth tracking because it is sold in research-chemical channels despite sparse therapeutic evidence.
• The current role in the repository is evidence triage: receptor-class plausibility with almost no outcome data.

Limits, risks, and missing evidence

• Current public evidence is mostly detection, ADME, and in silico toxicology rather than human outcome trials.
• Unknown product identity and exposure make anecdotal experience reports hard to interpret.
• SARM-class endocrine, lipid/liver, androgen-sensitive tissue, and doping concerns remain unresolved.

Risk flags

• research compound
• mechanistic only
• sarm class risk
• product identity risk
• doping

Linked papers, labels, and reviews

1. First multifaceted ADME profile of ACP-105
   forensic_toxicology / pubmed_acp105_adme_2025
   ADME and in silico toxicology work for ACP-105 in a doping/toxicology context.
2. Selective androgen receptor modulators in preclinical and clinical development
   review / pubmed_sarms_preclinical_clinical_2009
   SARM class review covering multiple preclinical and early clinical programs.